drugset / Trial / NCT04382768

Summary

The study aims to evaluate the reduction in severity and progression of lung injury with inhaled ibuprofen in patients with severe acute respiratory syndrome due to SARS-CoV-2 virus.

Timeline

Start
2020-05-01
Primary completion
2021-01
Completion
2021-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule 50 mg Inhaled